Global Prophylactic HIV Drugs Market Size Was Valued USD 53.9 Billion By 2035 |CAGR 4.36%

Global Prophylactic HIV Drugs Market Size Was Valued USD 53.9 Billion By 2035

According to a research report published by Spherical Insights & Consulting," The  Global Prophylactic HIV Drugs Market  Size Is Anticipated To Grow From USD 33.7 Billion In 2024 To USD 53.9 Billion By 2035, At a CAGR of 4.36% During The Forecast Period 2025-2035.

Browse 210 Market Data Tables And 45 Figures Spread Through 190 Pages and In-Depth TOC On the Global Prophylactic HIV Drugs Market Size, Share, and COVID-19 Impact Analysis, By Drug (Tenofovir Disoproxil Fumarate, Tenofovir Alafenamide, Emtricitabine, and More), By Dosage Form (Oral Pill, Long-Acting Injectable, and More), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and More), and By Region (North America, Europe, Asia-Pacific, Latin America, Middle East, and Africa), Analysis and Forecast 2025 – 2035. "Detailed Report Decription Here:   https://www.sphericalinsights.com/reports/prophylactic-hiv-drugs-market 

The prophylactic HIV drugs market focuses on medications designed to prevent HIV infection in high-risk populations, including healthcare workers, individuals with high-risk behaviors, and those living in regions with high HIV prevalence. These drugs, primarily used as pre-exposure prophylaxis (PrEP), are essential for controlling infection rates and reducing virus transmission. Market growth is driven by rising global HIV prevalence and increased awareness of preventive healthcare practices. Government initiatives, along with support from organizations such as WHO and UNAIDS, promote the adoption of preventive strategies. Advances in drug development, particularly long-acting injectable formulations, have enhanced effectiveness, convenience, and patient adherence, further fueling market expansion. The prophylactic HIV drugs market is restrained by high costs, limited access, and challenging daily regimens.

The tenofovir alafenamide segment dominated the market in 2024 and is projected to grow at a substantial CAGR during the forecast period.

Based on the drug, the prophylactic HIV drugs market is divided into tenofovir disoproxil fumarate, tenofovir alafenamide, emtricitabine, and more. Among these, the tenofovir alafenamide segment dominated the market in 2024 and is projected to grow at a substantial CAGR during the forecast period. The drug’s high effectiveness in preventing HIV, combined with a favorable safety profile and strong tolerability, has promoted widespread adoption among doctors and patients in developing nations’ healthcare sectors.

The oral pill segment accounted for the largest share in 2024 and is anticipated to grow at a remarkable CAGR during the forecast period.

Based on the dosage form, the prophylactic HIV drugs market is divided into oral pill, long-acting injectable, and more. Among these, the oral pill segment accounted for the largest share in 2024 and is anticipated to grow at a significant CAGR during the forecast period. Higher adoption of oral prophylactic HIV drugs is driven by clear prescription guidelines, lower costs compared to injectables, and improved adherence due to familiarity among healthcare providers and patients.

The hospital pharmacies segment accounted for the highest market revenue in 2024 and is anticipated to grow at a significant CAGR during the forecast period.

Based on the distribution channel, the prophylactic HIV drugs market is divided into hospital pharmacies, retail pharmacies, and more. Among these, the hospital pharmacies segment accounted for the highest market revenue in 2024 and is anticipated to grow at a significant CAGR during the forecast period. Hospital pharmacies remain the primary sites for administering prophylactic HIV drugs, particularly for high-risk patients, driven by clinical monitoring, hospital-based prevention programs, and global initiatives, boosting their market share.

North America is expected to hold the majority share of the global prophylactic HIV drugs market during the forecast period.

North America is expected to hold the majority share of the global prophylactic HIV drugs market during the forecast period. North America leads the prophylactic HIV drugs market due to high HIV awareness and advanced healthcare infrastructure supporting government prevention programs. The U.S. dominates with widespread PrEP and PEP use, insurance incentives, and public health support, while affordable drug costs and strong policies drive market growth.

Asia Pacific is anticipated to grow at the fastest pace in the global prophylactic HIV drugs market during the forecast period. The Asia-Pacific prophylactic HIV drugs market is growing due to rising HIV cases in India, China, and Thailand, supported by government health initiatives, increased awareness, risky behaviors, and improved future access to healthcare and preventive measures.

Major vendors in the global prophylactic HIV drugs market are Gilead Sciences, Roche, Cipla Ltd., Merck & Co., Mylan, Johnson & Johnson, ViiV Healthcare, Apotex Inc., Hetero Healthcare, AbbVie, Boehringer Ingelheim, Aurobindo Pharma Limited, Bristol-Myers Squibb, Teva Pharmaceutical Industries Ltd., and Others.

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting and Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Key Market Development 

• In July 2025, Merck (MSD) launched the EXPrESSIVE Phase 3 trials to evaluate MK-8527, a once-monthly oral NRTTI for HIV PrEP. EXPrESSIVE-11 targets high-risk individuals across 16 countries, while EXPrESSIVE-10, in collaboration with the Gates Foundation, focuses on women and adolescent girls in sub-Saharan Africa.

• In July 2025, ViiV Healthcare and the Medicines Patent Pool updated their voluntary licensing agreement to include patents for long-acting HIV regimens. The move follows WHO guidance recommending injectable cabotegravir plus rilpivirine as an effective HIV treatment option, expanding global access to long-acting therapies.

Market Segment

This study forecasts revenue at global, regional, and country levels from 2020 to 2035. Spherical Insights has segmented the prophylactic HIV drugs market based on the below-mentioned segments:

Global Prophylactic HIV Drugs Market, By Drug

• Tenofovir Disoproxil Fumarate
• Tenofovir Alafenamide
• Emtricitabine
• More

Global Prophylactic HIV Drugs Market, By Dosage Form

• Oral Pill
• Long-Acting Injectable
• More

Global Prophylactic HIV Drugs Market, By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• More

 Global Prophylactic HIV Drugs Market, By Regional Analysis

• North America
  • US
  • Canada
  • Mexico

• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe

• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Rest of Asia Pacific

• South America
  • Brazil
  • Argentina
  • Rest of South America
•  
• Middle East & Africa
  • UAE
  • Saudi Arabia
  • Qatar
  • South Africa
  • Rest of the Middle East & Africa

About the Spherical Insights & Consulting

Spherical Insights & Consulting is a market research and consulting firm which provides actionable market research study, quantitative forecasting and trends analysis provides forward-looking insight especially designed for decision makers and aids ROI.

Which is catering to different industry such as financial sectors, industrial sectors, government organizations, universities, non-profits and corporations. The company's mission is to work with businesses to achieve business objectives and maintain strategic improvements. 

CONTACT US:

For More Information on Your Target Market, Please Contact Us Below:    

Phone: +1 303 800 4326 (the U.S.)

Phone: +91 90289 24100 (APAC)

Email: inquiry@sphericalinsights.com, sales@sphericalinsights.com

Contact Us: https://www.sphericalinsights.com/contact-us

Follow Us: LinkedIn | Facebook | Twitter